Head and Neck Cancer (HNC) - Market Insight, Epidemiology And Market Forecast - 2032

This Head and Neck Cancer (HNC) - Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Head and neck cancer (HNC) historical and forecasted epidemiology as well as the Head and neck cancer (HNC) cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Head and Neck Cancer (HNC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Head and neck cancer (HNC) market size. The report also covers current Head and neck cancer (HNC) treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Head and Neck Cancer (HNC) Disease Understanding and Treatment

Head and Neck Cancer (HNC) Cancer Overview

HNC refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3-5% of all cancers in the US and are common in men and people over the age of 50. These cancers are easily preventable and can be treated if diagnosed early. The most common causes of HNC are tobacco and alcohol use, and nowadays, HPV has also emerged as an important risk factor. HNC usually begins in the squamous cells - often referred to as squamous cell carcinomas of the head and neck - that line the mucosal surfaces of the head and neck for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas.

Head and Neck Cancer Diagnosis

There are many tests used for diagnosing HNC. The doctor may consider these factors when choosing a diagnostic test:

• The type of cancer suspected
• Signs and symptoms
• Age and general health
• The results of earlier medical tests

If a person has symptoms and signs of HNC, the doctor will take a complete medical history, noting all symptoms and risk factors. In addition, the following tests may be used to diagnose HNC:

• Physical examination/blood and urine tests

During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood tests and urine tests may be done to help diagnose cancer.

• Endoscopy

An endoscopy allows the doctor to see inside the body with a thin, lighted, flexible tube called an endoscope. The person may be sedated as the tube is gently inserted through the nose into the throat and down the esophagus to examine the head and neck.

• Biopsy

A biopsy removes a small amount of tissue for examination under a microscope. A pathologist then analyzes the sample(s) removed during the biopsy. A common type of biopsy is called fine needle aspiration. This procedure collects cells using a thin needle inserted directly into the tumor or lymph node. The cells are examined under a microscope for cancer cells, called a cytologic examination.

• Biomarker testing of the tumor

The doctor may recommend running laboratory tests on a tumor sample to identify specific genes, proteins, and other factors unique to the tumor; also called molecular testing of the tumor, these tests help determine the treatment options.

Head and Neck Cancer Treatment

The main treatment options are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Surgery, radiation therapy, or a combination of these treatments are part of the treatment plan.

• Surgery

During surgery, the goal is to remove the cancerous tumor and some surrounding healthy tissue during an operation. Types of surgery for HNC include:

• Laser technology - This may be used to treat an early-stage tumor, especially if found in the larynx
• Excision - This is an operation to remove the cancerous tumor and some surrounding healthy tissue, known as a margin
• Lymph node dissection or neck dissection - If the doctor suspects cancer has spread, the doctor may remove lymph nodes in the neck. This may be done at the same time as an excision
• Reconstructive (plastic) surgery - If cancer surgery requires major tissue removal, such as removing the jaw, skin, pharynx, or tongue, reconstructive or plastic surgery may be done to replace the missing tissue.

Head and Neck Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Head and Neck Cancer, Molecular Alteration-specific Incident Cases of Head and Neck Cancer, and Stage-specific Incident Cases of Head and Neck Cancer, Site-specific Incident Cases of Head and Neck Cancer, HPV-specific Incident Cases of Head and Neck Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In 2021, the total incident cases of HNC in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.
• Among the European countries, Germany had the highest number of incident cases of HNC in 2021, i.e., ~20,000 cases, followed by France which had ~16,000 incident cases in 2021. On the other hand, Italy had the lowest incident cases of HNC, i.e. ~9900 cases in 2021. Japan had ~20,000 incident cases of HNC in 2021.
• The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distant with ~11,000 cases, and ~3,000 cases of the unknown stage.
• In 2021, the molecular alteration-specific incident cases of HNC in the US were maximum for TP53 at ~47,000 cases followed by CCND1, PIK3CA, NOTCH1, KMT2D, EGFR, NSD1, FGFR1, and HRAS mutations that had ~18,000 cases; ~14,000 cases; ~12,400 cases; ~12,000 cases; ~10,000 cases; ~6,500 cases; ~5,700 cases; and ~3,300 cases respectively.
• In 2021, the HPV status-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for HPV negative at ~40,000 cases followed by HPV positive at ~23,000 cases. By 2032, HPV status-specific incident cases of HNC are expected to increase significantly.

Head and Neck Cancer Epidemiology

The epidemiology segment provides the Head and Neck Cancer epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Drug Chapters

Head and Neck Cancer Emerging Drugs

TECENTRIQ (Atezolizumab): Hoffmann-La Roche

TECENTRIQ (Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) and aims to prevent cancer immune evasion. A Phase III trial evaluates TECENTRIQ in patients with adjuvant SCCHN (Roche, 2022). Atezolizumab binds to PD-L1 and blocks its interactions with both PD-1 and B7 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity (Genentech, 2022). It is under clinical development to treat locally advanced SCCHN as adjuvant therapy.

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. A humanized monoclonal antibody blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect tumor cells and healthy cells. KEYTRUDA is indicated for HNSCC in combination with platinum and fluorouracil (FU) for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC. As a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test, and as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

XEVINAPANT (debio 1143): Merck KGaA

XEVINAPANT (debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins) being investigated in the Phase III TrilynX study for previously untreated high-risk locally advanced LA SCCHN, in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy. It prevents the programmed cell death caused by chemoradiotherapy (CRT) and is believed to deprive tumors of one of their major resistance mechanisms, thereby increasing tumor cell sensitivity to CRT.

Toripalimab: Junshi Biosciences/Coherus

Toripalimab is an anti-PD-1 monoclonal antibody developed to block PD-1 interactions with its ligands, PD-L1, and PD-L2, and for enhanced receptor endocytosis function. PD-L1 and PD-L2 are tumor checkpoint proteins that recognize the PD-1 receptor on T-cell and exhaust their anti-tumor activity. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system's ability to attack and kill tumor cells.

Tipifarnib: Kura Oncology

Kura Oncology's lead drug candidate, tipifarnib, is a potent and highly selective inhibitor of farnesylation, a key cell signaling process in cancer initiation and development. Tipifarnib has been studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets, however, no molecular mechanism of action had previously been determined that could explain its activity across a range of diverse clinical indications, including squamous tumors that carry mutant HRAS, as well as in lymphoid, myeloid and solid tumors that do not carry HRAS mutations.

List to be continued in the report…

Head and Neck Cancer Market Outlook

HNC is a broad indication involving many site-specific cancers, such as laryngeal and hypopharyngeal cancer, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, oral and or pharyngeal cancer, and salivary gland cancer. Many cancers of the head and neck are curable, especially if detected at an early stage. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. When planning treatment, doctors consider how treatment might affect a person's quality of life, such as how a person feels, looks, talks, eats, and breathes.

Overall, the treatment approach for HNC patients can involve multiple options like surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are mainly used to destroy cancer cells, and they are either administered systematically or locally (by a medical oncologist). Pharmacological therapies being administered to a HNC patient can be chemotherapy, targeted therapy, or immunotherapy.

The HNSCC is the sixth most common cancer worldwide. Over 50% of patients with HNSCC are diagnosed with loco regionally advanced (Stage III) disease, whereas newly diagnosed metastatic HNSCC (Stage IVc) is uncommon (4% of newly diagnosed HNSCC). Patients with locoregionally advanced HNSCC typically receive multimodal treatment using surgery or radiation with or without chemotherapy.

Among all the available therapeutic options, chemotherapy is being extensively used in all lines of treatment. Multiple drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options have also been identified for treating HNC patients.

Key Findings

• The market size of Head and Neck Cancer in the 7MM was observed to be of USD 2,801 million in 2021.
• In 2021, the market size of Head and Neck Cancer in the US was of USD 1,831 million. Among the EU-5 countries, Germany had the highest market size for Head and Neck Cancer in 2021, i.e., USD 219 million. The lowest market size was estimated in Italy with USD 114 million in 2021.
• In Japan, the market size of Head and Neck Cancer was observed to be of USD 187 million in 2021.
• The market size of Head and Neck Cancer in The United States will grow at a CAGR of 8.2% by 2032.

The United States Market Outlook

This section provides the total Head and Neck Cancer market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Head and Neck Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Head and Neck Cancer market size and market size by therapies in Japan are provided.

Head and Neck Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Head and Neck Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Head and Neck Cancer Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Head and Neck Cancer emerging therapies.

Reimbursement Scenario in Head and Neck Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive market Intelligence analysis of the Head and Neck Cancer market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Head and Neck Cancer, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
• Comprehensive insight has been provided into the Head and Neck Cancer epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Head and Neck Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Head and Neck Cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Head and Neck Cancer market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Head and Neck Cancer market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Head and Neck Cancer. The launch of emerging therapies will significantly impact the Head and Neck Cancer market.
• This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Head and Neck Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• Head and Neck Cancer Pipeline Analysis
• Head and Neck Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Head and Neck Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Head and Neck Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Head and Neck Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions Answered

Market Insights:

• What was the Head and Neck Cancer market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Head and Neck Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Head and Neck Cancer market size during the forecast period (2022-2032)?
• At what CAGR, the Head and Neck Cancer market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the Head and Neck Cancer market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the Head and Neck Cancer market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Head and Neck Cancer?
• What is the historical Head and Neck Cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Head and Neck Cancer at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Head and Neck Cancer?
• Out of the above-mentioned countries, which country would have the highest population of Head and Neck Cancer during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Head and Neck Cancer along with the approved therapy?
• What are the current treatment guidelines for the treatment of Head and Neck Cancer?
• What are the Head and Neck Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Head and Neck Cancer?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Head and Neck Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Head and Neck Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Head and Neck Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for Head and Neck Cancer?
• What are the 7MM historical and forecasted market of Head and Neck Cancer?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving Head and Neck Cancer.
• To understand the future market competition in the Head and Neck Cancer market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for Head and Neck Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Head and Neck Cancer market.
• To understand the future market competition in the Head and Neck Cancer market.